← All trials
NCT05544656
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2019
- Primary completion
- Dec 31, 2023
- Completion date
- Jun 30, 2024
- First posted
- Sep 16, 2022
- Last posted
- Sep 16, 2022
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Semmelweis UniversityLead sponsor
- Semmelweis UniversityOverall official - principal investigator
- Semmelweis UniversityReponsible party - principal investigator
- Semmelweis UniversitySponsor investigator
- Semmelweis UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.